Aethlon Medical Debt to Equity Ratio 2010-2024 | AEMD
Current and historical debt to equity ratio values for Aethlon Medical (AEMD) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Aethlon Medical debt/equity for the three months ending June 30, 2024 was 0.00.
| Aethlon Medical Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.00B |
$0.01B |
0.31 |
| 2024-03-31 |
$0.00B |
$0.01B |
0.43 |
| 2023-12-31 |
$0.00B |
$0.01B |
0.37 |
| 2023-09-30 |
$0.00B |
$0.01B |
0.24 |
| 2023-06-30 |
$0.00B |
$0.01B |
0.21 |
| 2023-03-31 |
$0.00B |
$0.02B |
0.16 |
| 2022-12-31 |
$0.00B |
$0.02B |
0.20 |
| 2022-09-30 |
$0.00B |
$0.02B |
0.16 |
| 2022-06-30 |
$0.00B |
$0.02B |
0.15 |
| 2022-03-31 |
$0.00B |
$0.02B |
0.14 |
| 2021-12-31 |
$0.00B |
$0.02B |
0.07 |
| 2021-09-30 |
$0.00B |
$0.02B |
0.04 |
| 2021-06-30 |
$0.00B |
$0.03B |
0.05 |
| 2021-03-31 |
$0.00B |
$0.01B |
0.15 |
| 2020-12-31 |
$0.00B |
$0.01B |
0.11 |
| 2020-09-30 |
$0.00B |
$0.01B |
0.11 |
| 2020-06-30 |
$0.00B |
$0.02B |
0.08 |
| 2020-03-31 |
$0.00B |
$0.01B |
0.12 |
| 2019-12-31 |
$0.00B |
$0.00B |
0.23 |
| 2019-09-30 |
$0.00B |
$0.00B |
60.92 |
| 2019-06-30 |
$0.00B |
$0.00B |
1.88 |
| 2019-03-31 |
$0.00B |
$0.00B |
0.79 |
| 2018-12-31 |
$0.00B |
$0.00B |
0.56 |
| 2018-09-30 |
$0.00B |
$0.00B |
0.31 |
| 2018-06-30 |
$0.00B |
$0.01B |
0.26 |
| 2018-03-31 |
$0.00B |
$0.01B |
0.22 |
| 2017-12-31 |
$0.00B |
$0.01B |
0.25 |
| 2017-09-30 |
$0.00B |
$0.00B |
57.77 |
| 2017-06-30 |
$0.00B |
$-0.00B |
-1.54 |
| 2017-03-31 |
$0.00B |
$0.00B |
1.90 |
| 2016-12-31 |
$0.00B |
$0.00B |
716.82 |
| 2016-09-30 |
$0.00B |
$0.00B |
-8.13 |
| 2016-06-30 |
$0.00B |
$0.00B |
2.89 |
| 2016-03-31 |
$0.00B |
$0.00B |
0.68 |
| 2015-12-31 |
$0.00B |
$0.00B |
0.33 |
| 2015-09-30 |
$0.00B |
$0.00B |
0.21 |
| 2015-06-30 |
$0.00B |
$0.01B |
0.18 |
| 2015-03-31 |
$0.00B |
$0.00B |
1.12 |
| 2014-12-31 |
$0.00B |
$0.00B |
1.44 |
| 2014-09-30 |
$0.00B |
$-0.00B |
-1.33 |
| 2014-06-30 |
$0.01B |
$-0.00B |
-1.33 |
| 2014-03-31 |
$0.02B |
$-0.02B |
-1.12 |
| 2013-12-31 |
$0.01B |
$-0.01B |
-1.20 |
| 2013-09-30 |
$0.01B |
$-0.01B |
-1.04 |
| 2013-06-30 |
$0.01B |
$-0.01B |
-1.02 |
| 2013-03-31 |
$0.01B |
$-0.01B |
-1.05 |
| 2012-12-31 |
$0.01B |
$-0.01B |
-1.04 |
| 2012-09-30 |
$0.01B |
$-0.01B |
-1.06 |
| 2012-06-30 |
$0.01B |
$-0.01B |
-1.10 |
| 2012-03-31 |
$0.01B |
$-0.01B |
-1.09 |
| 2011-12-31 |
$0.01B |
$-0.01B |
-1.15 |
| 2011-09-30 |
$0.01B |
$-0.01B |
-1.05 |
| 2011-06-30 |
$0.01B |
$-0.01B |
-1.05 |
| 2011-03-31 |
$0.01B |
$-0.01B |
-1.10 |
| 2010-12-31 |
$0.01B |
$-0.01B |
-1.10 |
| 2010-09-30 |
$0.01B |
$-0.01B |
-1.18 |
| 2010-06-30 |
$0.01B |
$-0.01B |
-1.11 |
| 2010-03-31 |
$0.01B |
$-0.00B |
-1.15 |
| 2009-12-31 |
$0.00B |
$-0.00B |
-1.07 |
| 2009-09-30 |
$0.00B |
$-0.00B |
-1.07 |
| 2009-06-30 |
$0.00B |
$-0.00B |
-1.08 |
| 2009-03-31 |
$0.00B |
$-0.00B |
-1.05 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Health Maintenance Organizations |
$0.005B |
$0.001B |
|
Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India.
|
